For laboratory research use only. Not for human or veterinary use. Read our research-use policy

Analytical methods

N- and C-terminal modifications and mass spectrometry

Many research peptides are not plain chains: they carry an acetyl cap, a C-terminal amide or a pyroglutamate. Each is an exact, computable mass shift. This primer tabulates them, rebuilds the formulas of 12 library peptides, and shows what each cap does to the ions an instrument reports.

Published 19 November 2026 · Last updated 19 November 2026

A linear peptide with free termini has the composition of its residues plus one water. Everything else on a peptide's label, an Ac- in front or -NH2 at the end, is a deviation from that baseline. Our modifications overview introduces the common ones and the PTM primer covers glycosylation; this page is about the two ends of the chain.

Why the termini matter

Yonekura et al. (2023) note that more than half of neural and endocrine peptides, such as VIP and oxytocin, have an alpha-amide at the C-terminus, and describe it as essential for biological activity; Merkler (1994) summarised structure-activity data for 45 bioactive peptides showing that the C-terminal amide is required for the full activity of most amidated peptide hormones. Abraham and Podell (1981) review N-terminal pyroglutamic acid, which the strongest evidence derives from glutamine, using thyrotropin-releasing factor as the example. For a laboratory, the practical point is that a cap changes both what a mass spectrometer should report and what a chromatography run does, and a certificate can only confirm identity if it matches the right end groups.

The mass shifts

Terminal and related modifications as exact composition changes (monoisotopic mass, computed from the formulas with NIST isotope masses)
ModificationComposition changeMonoisotopic shift (Da)Where it appears in our libraryWhat follows
N-terminal acetylation+C2H2O+42.0106TB-500 as listed, thymosin alpha-1, melanotans, PT-141Removes the N-terminal positive charge; b ions shift by the same amount
C-terminal amidation−O +NH (OH becomes NH2)−0.9840Kisspeptin-10, VIP, oxytocin, melanotans, SS-31, ipamorelin, dihexaRemoves the C-terminal negative charge; y ions shift by the same amount
Deamidation of Asn or Gln, or amide read as acid+O −NH+0.9840Any peptide with Asn or Gln; any amidated peptideThe same +0.984 Da as a C-terminal acid impurity in an amidated peptide
N-terminal pyroglutamate from Gln−NH3−17.0265ARA-290 (listed as pGlu-EQLERALNSS)The cyclised form eluted later on reversed-phase HPLC in one study (Khandke et al., 1989)
N-terminal pyroglutamate from Glu−H2O−18.0106None in the library; relevant to any N-terminal GluRate depends on pH (Chelius et al., 2006)
Disulfide bond−H2−2.0157Oxytocin, AOD-9604Counted per bond; reduction adds it back
Side-chain lactam ring−H2O−18.0106Melanotan II, PT-141Closes the Asp–Lys ring
N-terminal hexanoyl+C6H10O+98.0732DihexaA fatty acyl cap, not a conventional residue

Rebuilding 12 library formulas from residues and caps

To check the caps, each formula below is rebuilt from the residues of the structure, plus the modifications, and compared with the formula in the compound record. Norleucine has the same composition as leucine, and D-amino acids have the same composition as their L forms, so mass spectrometry cannot distinguish them from the standard residues; Aib, Dmt, 2-Nal and 6-aminohexanoic acid are added by their own residue formulas.

Library peptides with capped termini: formula rebuilt from the residues plus the modifications, compared with the PubChem formula on each compound page
PeptideStructure as listedFree-termini formulaModifications appliedRebuilt formulaMatches PubChemMonoisotopic mass (Da)[M+H]+[M+2H]2+Shift from the capped termini (Da)
TB-500 (as listed)Ac-LKKTETQC36H66N10O13N-terminal acetylC38H68N10O14Yes888.4916889.4989445.2531+42.0106
Thymosin alpha-1Ac-SDAAVDTSSEITTKDLKEKKEVVEEAENC127H213N33O54N-terminal acetylC129H215N33O55Yes3106.50413107.51141554.2593+42.0106
Kisspeptin-10YNWNSFGLRF-NH2C63H82N16O15C-terminal amideC63H83N17O14Yes1301.63051302.6378651.8225−0.9840
VIPHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2C147H237N43O43SC-terminal amideC147H238N44O42SYes3323.75613324.76341662.8853−0.9840
OxytocinCYIQNCPLG-NH2, Cys1–Cys6 disulfideC43H67N11O13S2C-terminal amide; Disulfide bondC43H66N12O12S2Yes1006.43651007.4437504.2255−0.9840
ARA-290pGlu-EQLERALNSSC51H87N17O21N-terminal pyroglutamate (from Gln)C51H84N16O21Yes1256.59971257.6070629.3071−17.0265
Melanotan IAc-SYSNle-EH-D-Phe-RWGKPV-NH2C76H108N20O19N-terminal acetyl; C-terminal amideC78H111N21O19Yes1645.83651646.8438823.9255+41.0265
Melanotan IIAc-Nle-cyclo[DH-D-Phe-RWK]-NH2C48H68N14O10N-terminal acetyl; C-terminal amide; Side-chain lactam ringC50H69N15O9Yes1023.54031024.5475512.7774+41.0265
PT-141Ac-Nle-cyclo[DH-D-Phe-RWK]-OHC48H68N14O10N-terminal acetyl; Side-chain lactam ringC50H68N14O10Yes1024.52431025.5316513.2694+42.0106
SS-31D-Arg-Dmt-KF-NH2C32H48N8O6C-terminal amideC32H49N9O5Yes639.3857640.3929320.7001−0.9840
IpamorelinAib-H-D-2Nal-D-Phe-K-NH2C38H48N8O6C-terminal amideC38H49N9O5Yes711.3857712.3929356.7001−0.9840
DihexaHexanoyl-YI-Ahx-NH2C21H33N3O5N-terminal hexanoyl; C-terminal amideC27H44N4O5Yes504.3312505.3384253.1729+97.0891

All 12 rebuilt formulas equal the PubChem formulas in the compound records, so the terminal and ring modifications listed on those pages are internally consistent with their masses. The column on the right is the net shift from the capped termini alone: for example, kisspeptin-10 is −0.9840 Da from the same sequence with free termini, and melanotan I is +41.0265 Da (acetyl plus amide).

What the caps do to fragment ions

In tandem mass spectrometry the peptide backbone breaks at the amide bonds. Under the nomenclature of Roepstorff and Fohlman (1984), the fragment that keeps the N-terminus is a b ion and the one that keeps the C-terminus is a y ion. A b ion is the sum of its residue masses plus a proton (1.0073); a y ion is the sum of its residue masses plus water plus a proton. A modification at an end therefore moves only the fragments that contain that end, by the full shift:

Singly charged b and y ions with and without the end group (m/z, computed)
IonWithout the capWith the capShiftComparison
Kisspeptin-10 y1 (…F)166.0863165.1022−0.9840Free acid vs C-terminal amide
Kisspeptin-10 y2 (…RF)322.1874321.2034−0.9840Free acid vs C-terminal amide
Kisspeptin-10 y3 (…LRF)435.2714434.2874−0.9840Free acid vs C-terminal amide
Thymosin alpha-1 b1 (S…)88.0393130.0499+42.0106Free N-terminus vs N-acetyl
Thymosin alpha-1 b2 (SD…)203.0662245.0768+42.0106Free N-terminus vs N-acetyl
Thymosin alpha-1 b3 (SDA…)274.1034316.1139+42.0106Free N-terminus vs N-acetyl
ARA-290 b2 (QE…)258.1084241.0819−17.0265Gln at the N-terminus vs pyroglutamate
ARA-290 b3 (QEQ…)386.1670369.1405−17.0265Gln at the N-terminus vs pyroglutamate

Reading these in a spectrum, the y1 ion of kisspeptin-10 is 165.1022 if the C-terminus is the amide the compound record describes and 166.0863 if it is the acid, which shows the end group directly without any assumption about the precursor. Mouls et al. (2006) synthesised two sets of 76 amidated and carboxylated peptides and found that C-terminal amidated peptides, in most cases, lost ammonia abundantly on low-energy collision-induced dissociation; they also found that arginine, and to a lesser extent lysine, can produce a competing ammonia loss from the side chain, which interferes with the signature. Kisspeptin-10 contains an arginine, so that interference is possible there.

Amide or acid: a 1 Da problem

The amide is 0.9840 Da lighter than the acid, and a 13C isotope adds 1.0034 Da, so the second peak of an amide's isotope envelope almost coincides with the first peak of the acid. Logerot et al. (2022) describe exactly this problem: the only 1 Da mass difference between the amidated and the carboxylated forms produces overlapping isotopic contributions of both molecular ions, which they address with energy-resolved MS/MS.

For kisspeptin-10 (amide 1301.6305 Da, formula C63H83N17O14; acid C63H82N16O15) the numbers are:

  • The amide's M+1 peak has a relative intensity of 0.758 of its monoisotopic peak.
  • The acid's monoisotopic peak lies 0.0193 Da from the amide's 13C peak.
  • Separating the two at m/z 1303.6 (singly charged) needs a resolving power, m divided by Δm, of about 67,409.

On a low-resolution instrument, a few percent of acid in an amidated peptide is therefore buried in the amide's M+1 peak, and the same +0.984 Da step is what Asn or Gln deamidation produces. Kuyama et al. (2009) tackle the ambiguity chemically: converting the free carboxyl group to a methylamide raises the acid-to-amide difference from 1 to 14 Da. Retention time against a reference sample of each form is the other practical tool (HPLC and LC-MS together).

Pyroglutamate

ARA-290 is listed as pGlu-EQLERALNSS, so its first residue is a cyclised glutamine, and the pyroglutamate form is 1256.5997 Da. The uncyclised, open Gln form would be 1273.6262 Da, 17.0265 Da heavier. Khandke et al. (1989) saw the cyclised form of N-terminal glutamine peptides elute later on reversed-phase HPLC, with a mass loss of ammonia and an apparent increase in hydrophobicity, and reported nearly 44% conversion of glutaminyl peptides to pyroglutamyl peptides in 24 hours at 37 °C in 0.2 M ammonium bicarbonate; conversion was faster in sodium phosphate, significantly slower in ammonium acetate, and essentially absent at 0 °C. Chelius et al. (2006) showed that N-terminal glutamic acid also cyclises in antibodies, with minimal formation at pH 6.2 and more at pH 4 and pH 8. For a peptide meant to start with pyroglutamate, an open-form peak 17.03 Da heavier is the thing to look for.

A decoder for terminal mass differences

Observed minus expected neutral mass, and the terminal explanations that fit (candidate only; MS/MS is needed to place the change)
Observed − expected (Da)Candidate explanations
+0.984Free acid where an amide is expected; deamidation of Asn or Gln. Overlaps the 13C peak (+1.003) at low resolution.
−0.984Amide where a free acid is expected.
+42.011Acetylation (C2H2O). Trimethylation (C3H6) is +42.047 Da, 0.0364 Da apart, about 36 ppm at 1000 Da, so the two need accurate mass or MS/MS to separate.
−17.027Pyroglutamate formed from an N-terminal Gln.
−18.011Loss of water: pyroglutamate from N-terminal Glu, ring closure, or dehydration.
−2.016One more disulfide (or a lost reduction).

What to ask of a COA

  • The structure on the certificate states both end groups, not just the sequence, so the expected mass includes them.
  • The observed mass is compared with the mass of that capped structure, with the instrument's resolution and accuracy stated.
  • For amidated peptides, the report says how the acid form was excluded, with retention time, high resolution, or MS/MS.
  • For compounds listed with unusual caps or non-standard residues, as for the entries in the table above, the formula can be checked against PubChem the way this page does it.

Most of our compound pages already report formula and mass computed from the structure as listed; the supplier's mass-spectrometry result for a batch is the thing that confirms them, and for our products the COA field reads "Not yet provided".

Related

References

  1. Roepstorff P, Fohlman J (1984). Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomed Mass Spectrom 11:601. PubMed 6525415 · DOI
  2. Mouls L, Subra G, Aubagnac JL, et al. (2006). Tandem mass spectrometry of amidated peptides. J Mass Spectrom 41:1470-83. PubMed 17072914 · DOI
  3. Logerot E, Cazals G, Memboeuf A, et al. (2022). Revealing C-terminal peptide amidation by the use of the survival yield technique. Anal Biochem 655:114823. PubMed 35921876 · DOI
  4. Kuyama H, Nakajima C, Nakazawa T, et al. (2009). A new approach for detecting C-terminal amidation of proteins and peptides by mass spectrometry in conjunction with chemical derivatization. Proteomics 9:4063-70. PubMed 19658105 · DOI
  5. Merkler DJ (1994). C-terminal amidated peptides: production by the in vitro enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity. Enzyme Microb Technol 16:450-6. PubMed 7764886 · DOI
  6. Yonekura H, Kato I, Yamamoto Y, et al. (2023). Biosynthesis and Function of VIP and Oxytocin: Mechanisms of C-terminal Amidation, Oxytocin Secretion and Transport. Endocrinology 164. PubMed 37548257 · DOI
  7. Abraham GN, Podell DN (1981). Pyroglutamic acid. Non-metabolic formation, function in proteins and peptides, and characteristics of the enzymes effecting its removal. Mol Cell Biochem 38 Spec No:181-90. PubMed 6117006 · DOI
  8. Khandke KM, Fairwell T, Chait BT, et al. (1989). Influence of ions on cyclization of the amino terminal glutamine residues of tryptic peptides of streptococcal PepM49 protein. Resolution of cyclized peptides by HPLC and characterization by mass spectrometry. Int J Pept Protein Res 34:118-23. PubMed 2807728 · DOI
  9. Chelius D, Jing K, Lueras A, et al. (2006). Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal Chem 78:2370-6. PubMed 16579622 · DOI
  10. NIST, Atomic Weights and Isotopic Compositions with Relative Atomic Masses, physics.nist.gov: isotope masses and natural abundances used for the computed values on this page.
  11. PubChem, compound records for the formulas used in the rebuilt-formula table, linked from each peptide's compound page.

Frequently asked questions

How much does a C-terminal amide change the mass?

Replacing the carboxylic acid OH with NH2 lowers the monoisotopic mass by 0.9840 Da, so an amidated peptide is almost exactly 1 Da lighter than the free acid of the same sequence.

Why is it hard to tell an amide from an acid by mass alone?

Logerot et al. (2022) point out that the only 1 Da mass difference produces overlapping isotopic contributions of the two molecular ions. For kisspeptin-10 the gap between the acid peak and the amide's 13C peak is about 0.019 Da, which needs a resolving power near 67000.

What does N-terminal acetylation do?

It adds C2H2O, 42.0106 Da, removes the N-terminal positive charge, and shifts every b ion by the same amount; thymosin alpha-1 and the melanotans carry it.

What is pyroglutamate?

A cyclised N-terminus formed from glutamine (loss of NH3) or glutamic acid (loss of water); ARA-290 is listed with an N-terminal pyroglutamate, and the cyclised form of a glutaminyl peptide elutes later on reversed-phase HPLC in the study of Khandke et al. (1989).

Do the library formulas on this page match PubChem?

Yes. Rebuilding each formula from the residues plus its modifications reproduces the PubChem formula for all 12 peptides in the table.